Warfarin maintenance dosages in the very elderly

American Journal of Health-System Pharmacy

Volumn 62, Issue 10, 2005, Pages 1062-1066

  Singla, Dana L ^a   Morrill, Gregory B ^b  

^a MIDWESTERN UNIVERSITY   (United States)

^b PFIZER INC   (United States)

Author keywords

Age; Anticoagulants; Dosage; Geriatrics; Warfarin

Indexed keywords

WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTERY DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DRUG DOSE REGIMEN; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; STROKE; TRANSIENT ISCHEMIC ATTACK;

EID: 18744390495     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/62.10.1062     Document Type: Review

References (23)

1. Chrischilles EA, Foley DJ, Wallace RB et al. Use of medications by persons 65 and over: data from the established populations for epidemiological studies of the elderly. J Gerontol 1992; 47:M137-44.
2. Greenblatt DJ, Sellers EM, Shader RI. Drug therapy: drug disposition in old age. N Engl J Med. 1982; 306:1081-8.
3. Fihn SD, McDonnell M, Martin D et al. Risk factors for complications of chronic anticoagulation. A multi-center study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med. 1993; 118:511-20.
4. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994; 120:897-902.
5. Palareti G, Leali N, Coccheri S et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet. 1996; 348:423-8.
6. Van der Meer FJ, Rosendaal FR, Vandenbroucke JP et al. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med. 1993; 153:1557-62.
7. Routledge PA, Chapman PH, Davies DM et al. Factors affecting warfarin requirements. A prospective population study. Eur J Clin Pharmacol. 1979; 15:319-22.
8. Dobrzanski S, Duncan SE, Harkiss A et al. Age and weight as determinants of warfarin requirements. J Clin Hosp Pharm. 1983; 8:75-7.
9. Redwood M, Taylor C, Bain BJ et al. The association of age with dosage requirement for warfarin. Age Ageing. 1991; 20:217-20.
10. Gurwitz JH, Avorn J, Ross-Degnan D et al. Aging and the anticoagulant response to warfarin. Ann Intern Med. 1992; 116:901-4.
11. James AH, Britt RP, Raskino CL et al. Factors affecting the maintenance dose of warfarin. J Clin Pathol. 1992; 45:704-6.
12. Wynne HA, Kamali F, Edwards C et al. Effect of ageing upon warfarin dose requirements: a longitudinal study. Age Ageing. 1996; 25:429-31.
13. Hylek EM, Regan S, Hughes R et al. Effect of age on maintenance warfarin dose among outpatients with an International Normalized Ratio (INR) target intensity of 2-3. Circulation. 2000; 102(suppl 2):428. Abstract.
14. Hylek EM. Oral anticoagulants. Pharmacologic issues for use in the elderly. Clin Geriatr Med. 2001; 17:1-13.
15. Ansell JE, Hirsh J, Poller L et al. The pharmacology and management of the vitamin K antagonists. Chest. 2004; 126:204S-33S.
16. U.S. Department of Health and Human Services. A profile of older Americans: 2003. www.aoa.gov/about/annual_report/ar_full.pdf (accessed 2004 Sep).
17. Harkness R, Bratman R. The natural pharmacist: drug-herb-vitamin interactions bible. Rocklin, CA: Prima Health; 2000.
18. Drug Facts and Comparisons, Herbal interaction facts, www.efactsweb.com (accessed 2002 Jun).
19. Tatro DS, ed. Drug interaction facts 2001. 9th ed. St. Louis: Facts and Comparisons; 2001.
20. Breckenridge A, Orme M, Wesseling H et al. Pharmacokinetics and pharmacodynamics or the enantiomers of warfarin in man. Clin Pharmacol Ther. 1974; 15:424-30.
21. O'Reilly RA. Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther. 1974; 16:348-54.
22. Aithal GP, Day CP, Kesteven PJ et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999; 353:717-9.
23. Kamali F, Khan TI, King BP et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther. 2004; 75:204-12.